Press release
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data
About this update from Amgen Inc.
[{"type":"text","content":"Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm\nNew Data Reinforce KYPROLIS® (carfilzomib) as an Important Treatment Option for Relapsed or Refractory Multiple Myeloma\nAdditional Analyses Support Eculizumab (a biosimilar candidate to SOLIRIS®) as a Potential Option in Paroxysmal Nocturnal Hemoglobinuria\nTHOUSAND OAKS, Calif., Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.\n\"Data at this year's ASH meeting illustrate the expanding potential of our innovative hematology medicines, BLINCYTO and KYPROLIS, as well as our commitment to providing additional treatment options with our biosimilar eculizumab,\" said David M. Reese, M.D., executive vice president of Research and Development at Amgen. \"As the pioneer of T-cell engager technology and building on nearly a decade of real-world experience, we continue to advance our first-in-class BiTE® molecule, BLINCYTO, into earlier lines of treatment where we have seen encouraging data in patients living with acute lymphoblastic leukemia.\"\nAbstracts are available on the ASH website.\nKey Abstracts and Presentation Times:\nAmgen Sponsored Abstracts\nKYPROLIS® (carfilzomib)\nReal-World Outcomes for Relapsed or Refractory Multiple Myeloma Patients Treated with Lenalidomide and Daratumumab Sparing Triplet Regimens: A United States Retrospective Cohort StudyAbstract #4705, Session #652, Monday, December 11 from 6:00 - 8:00 p.m. PTEculizumab (investigational biosimilar ABP 959 candidate to SOLIRIS®)\nEfficacy of Parallel and Crossover Analysis As Well As Pharmacokinetic Similarity Were Confirmed between ABP 959 and Eculizumab Reference Product in Patients with PNHAbstract #4092, Session #508, Monday, December 11 from 6:00 - 8:00 p.m. PTInvestigator Sponsored Studies\nBLINCYTO® (blinatumomab)\nChemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Updates From a Phase II TrialAbstract #2827, Session #612, Sunday, December 10 from 6:00 - 8:00 p.m. PTPhase II Study of Low-Intensity Chemothe...